NASDAQ:ACRX - AcelRx Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AcelRx Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.55 -0.06 (-3.73 %) (As of 02/23/2020 03:36 PM ET) Add Compare Today's Range$1.54Now: $1.55▼$1.6350-Day Range$1.49MA: $1.78▼$2.0752-Week Range$1.48Now: $1.55▼$4.09Volume858,540 shsAverage Volume609,070 shsMarket Capitalization$123.33 millionP/E RatioN/ADividend YieldN/ABeta2.11 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACRX Previous Symbol CUSIPN/A CIK1427925 Webhttp://www.acelrx.com/ Phone650-216-3500Debt Debt-to-Equity RatioN/A Current Ratio7.49 Quick Ratio7.23Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.15 million Price / Sales57.36 Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book31.00Profitability EPS (Most Recent Fiscal Year)($0.81) Net Income$-47,150,000.00 Net Margins-2,116.81% Return on EquityN/A Return on Assets-45.26%Miscellaneous Employees61 Outstanding Shares79,570,000Market Cap$123.33 million Next Earnings Date3/5/2020 (Estimated) OptionableOptionable Receive ACRX News and Ratings via Email Sign-up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ACRX Rates by TradingView AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions What is AcelRx Pharmaceuticals' stock symbol? AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX." How were AcelRx Pharmaceuticals' earnings last quarter? AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced its quarterly earnings results on Wednesday, November, 6th. The specialty pharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.07. The specialty pharmaceutical company had revenue of $0.61 million for the quarter, compared to analysts' expectations of $1.22 million. View AcelRx Pharmaceuticals' Earnings History. When is AcelRx Pharmaceuticals' next earnings date? AcelRx Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for AcelRx Pharmaceuticals. What guidance has AcelRx Pharmaceuticals issued on next quarter's earnings? AcelRx Pharmaceuticals issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.3-2.3 million, compared to the consensus revenue estimate of $2.82 million. What price target have analysts set for ACRX? 4 equities research analysts have issued 1 year price objectives for AcelRx Pharmaceuticals' stock. Their forecasts range from $2.00 to $10.00. On average, they expect AcelRx Pharmaceuticals' stock price to reach $6.88 in the next twelve months. This suggests a possible upside of 343.5% from the stock's current price. View Analyst Price Targets for AcelRx Pharmaceuticals. What is the consensus analysts' recommendation for AcelRx Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AcelRx Pharmaceuticals. What are Wall Street analysts saying about AcelRx Pharmaceuticals stock? Here are some recent quotes from research analysts about AcelRx Pharmaceuticals stock: 1. According to Zacks Investment Research, "AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. " (1/8/2020) 2. LADENBURG THALM/SH SH analysts commented, "We are not at all dismayed by the relatively small revenues since there is no stocking for this direct shipment product and hospital formularies barely had an opportunity to meet during these five weeks. Management did note that among the five hospital formularies that did meet, all five have approved Dsuvia. Presently, the company knows of 41 more meetings by midyear. If approved, it will still take weeks to months for AcelRx’s Dsuvia reps to find time with these busy hospital/ASC healthcare practitioners (HCPs), REMS training to be completed (relatively brief however) and the product to be stocked. As many investors know, hospital launches are notoriously slow. However, the early signals are ahead of our expectations." (5/9/2019) Has AcelRx Pharmaceuticals been receiving favorable news coverage? Headlines about ACRX stock have trended negative this week, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. AcelRx Pharmaceuticals earned a coverage optimism score of -2.4 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for AcelRx Pharmaceuticals. Are investors shorting AcelRx Pharmaceuticals? AcelRx Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 10,800,000 shares, an increase of 6.9% from the January 15th total of 10,100,000 shares. Based on an average trading volume of 1,020,000 shares, the days-to-cover ratio is currently 10.6 days. Approximately 13.8% of the shares of the company are short sold. View AcelRx Pharmaceuticals' Current Options Chain. Who are some of AcelRx Pharmaceuticals' key competitors? Some companies that are related to AcelRx Pharmaceuticals include Milestone Pharmaceuticals (MIST), Viking Therapeutics (VKTX), CytoDyn (CYDY), Satsuma Pharmaceuticals (STSA), Prothena (PRTA), Cue Biopharma (CUE), BioDelivery Sciences International (BDSI), BioSpecifics Technologies (BSTC), Organogenesis (ORGO), Sinovac Biotech (SVA), Beyondspring (BYSI), ProQR Therapeutics (PRQR), Merus (MRUS), Progenics Pharmaceuticals (PGNX) and Innate Pharma (IPHYF). What other stocks do shareholders of AcelRx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Amarin (AMRN), Amicus Therapeutics (FOLD), Novavax (NVAX), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX), Cyberark Software (CYBR), Fitbit (FIT) and Synergy Pharmaceuticals (SGYP). Who are AcelRx Pharmaceuticals' key executives? AcelRx Pharmaceuticals' management team includes the folowing people: Mr. Vincent J. Angotti, CEO & Director (Age 51)Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 56)Mr. Raffi Mark Asadorian, Chief Financial Officer (Age 50)Mr. Lawrence G. Hamel, Chief Devel. Officer (Age 67)Mr. Anil N. Dasu, Chief Engineering Officer (Age 56) Who are AcelRx Pharmaceuticals' major shareholders? AcelRx Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (1.74%), Geode Capital Management LLC (1.37%), Cornerstone Capital Inc. (0.62%), Marshall Wace LLP (0.23%), UBS Group AG (0.16%) and Mercer Global Advisors Inc. ADV (0.13%). Company insiders that own AcelRx Pharmaceuticals stock include Badri N Dasu, Lawrence G Hamel, Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View Institutional Ownership Trends for AcelRx Pharmaceuticals. Which major investors are selling AcelRx Pharmaceuticals stock? ACRX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Cedar Wealth Management LLC, New York State Common Retirement Fund, Mercer Global Advisors Inc. ADV, State Street Corp and Lincoln Capital Corp. View Insider Buying and Selling for AcelRx Pharmaceuticals. Which major investors are buying AcelRx Pharmaceuticals stock? ACRX stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Geode Capital Management LLC, Ahrens Investment Partners LLC, California Public Employees Retirement System, Cornerstone Capital Inc., UBS Group AG, Barclays PLC and Citigroup Inc.. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View Insider Buying and Selling for AcelRx Pharmaceuticals. How do I buy shares of AcelRx Pharmaceuticals? Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is AcelRx Pharmaceuticals' stock price today? One share of ACRX stock can currently be purchased for approximately $1.55. How big of a company is AcelRx Pharmaceuticals? AcelRx Pharmaceuticals has a market capitalization of $123.33 million and generates $2.15 million in revenue each year. The specialty pharmaceutical company earns $-47,150,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. AcelRx Pharmaceuticals employs 61 workers across the globe.View Additional Information About AcelRx Pharmaceuticals. What is AcelRx Pharmaceuticals' official website? The official website for AcelRx Pharmaceuticals is http://www.acelrx.com/. How can I contact AcelRx Pharmaceuticals? AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected] MarketBeat Community Rating for AcelRx Pharmaceuticals (NASDAQ ACRX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 432 (Vote Outperform)Underperform Votes: 369 (Vote Underperform)Total Votes: 801MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/23/2020 by MarketBeat.com StaffFeatured Article: How does a security become overbought?
